CLOROTEPINE MESYLATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H21ClN2S.CH4O3S
Molecular Weight	441.007
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.CN1CCN(CC1)C2CC3=CC=CC=C3SC4=CC=C(Cl)C=C24

InChI

InChIKey=XQRUOHZMMIUQSB-UHFFFAOYSA-N

InChI=1S/C19H21ClN2S.CH4O3S/c1-21-8-10-22(11-9-21)17-12-14-4-2-3-5-18(14)23-19-7-6-15(20)13-16(17)19;1-5(2,3)4/h2-7,13,17H,8-12H2,1H3;1H3,(H,2,3,4)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6893891 | https://www.ncbi.nlm.nih.gov/pubmed/1676758 | https://www.scribd.com/document/111549549/Annual-Drug-Data-Report-Vol-1-1971 | http://www.archiv.muni.cz/media/27661/rysanek-konrad.pdf

Clorotepine (aka octoclothepin or octoclothepine) is an antipsychotic from the tricyclic group derived from perathiepin. It was originally developed in 1965 and marketed in the Czech Republic by Spofa in or around 1971 for the treatment of schizophrenic psychosis. Clorotepine has a high affinity for the dopamine (D1, D2, D3, D4), receptors the serotonin 5-HT (2A, 2B, 2C, 6, 7) receptors, the alpha-adrenergic receptors (1A, 1B, 1D), and the histamine H1 receptors. In most instances, it acts as an antagonist (or inverse agonist). Clorotepine will also block the reuptake of norepinephrine by inhibiting the norepinephrine transporter.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
5-hydroxytryptamine receptor 2A 69 Target ID: P28223 Gene ID: 3356.0 Gene Symbol: HTR2A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1676758	Antagonist 2778	0.57 nM [IC50]
Alpha-1A adrenergic receptor 19 Target ID: P35348\|\|\|B0ZBD9\|\|\|Q6RUJ8 Gene ID: 148.0 Gene Symbol: ADRA1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1676758	Antagonist 2778	0.18 nM [IC50]
D(1A) dopamine receptor 18 Target ID: P21728 Gene ID: 1812.0 Gene Symbol: DRD1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1676758	Antagonist 2778	2.2 nM [IC50]
D(2) dopamine receptor 58 Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1676758	Antagonist 2778	2.4 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Schizophrenia 298 Sources: https://www.ncbi.nlm.nih.gov/pubmed/5040177	Primary	Not Provided 504	Clotepin Approved Use Unknown
Endogenous depression 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/5040142	Primary	Not Provided 504	Clotepin Approved Use Unknown
Hyperkinetic disorder 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1973018	Primary	Not Provided 504	Clotepin Approved Use Unknown

PubMed

Title	Date	PubMed
Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings.	1978 Dec	31480
Further clinical experiences with optical isomers of the L and D clorothepin.	1979	263672
On acute effects of some drugs on the higher nervous activity in man. Clorotepin (2 mg), its (+)-enantiomer (2 mg) and (-)-enantiomer (2 mg).	1980	6231812
Octoclothepin enantiomers. A reinvestigation of their biochemical and pharmacological activity in relation to a new receptor-interaction model for dopamine D-2 receptor antagonists.	1991 Jul	1676758

Patents

Sample Use Guides

In Vivo Use Guide

Clorotepin is provided in doses up to 2 mg.

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Name

Type

Language

CLOROTEPINE MESYLATE

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID00962538